JAZZ boosts outlook as Q2 revenue and pipeline expansion support growth
JAZZ reported record Q2 revenue and broad portfolio growth, citing resilient brands and successful new launches. Ziihera peak sales outlook increased to $3–$5 billion, with expansion into multiple cancer indications.